anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A plastid transformation vector for a stably transforming a plastid genome is provided. The vector includes, as operably-linked components, a first flanking sequence, a DNA sequence coding for a therapeutic human IFN, which is capable of expression in the plastid and a second flanking sequence. The invention also provides isolated and purified IFN, wherein the IFN is configured in a monomeric or multimeric form and is a structural equivalent to orally administered human IFN. Also provided are methods for variable-expressing biopharmaceutical proteins in plants suitable for mammal consumption. The method includes integrating a plastid transformation vector into a plastid genome of a plant cell; growing the plant cell to express a biopharmaceutical protein, such as therapeutic human interferon IFN. Also disclosed are plants transformed with the aforementioned vectors, and the progeny thereof. Also, disclosed is the IFN, which is IFNα2b.
Watching and listening to in-depth, college-level lectures on art, history and science on the computer. Participants perform assigned mental activities 60 minutes/day, 3 days/week for 12 weeks.
At present, hypoxia is still the main cause of complications and death during perioperative period. Compared with adults, children have lower functional residual volume and lower tolerance to hypoxia caused by apnea due to their special physiological and functional characteristics. During anesthesia induction and tracheal intubation, spontaneous breathing completely disappears. At this critical stage, hypoxemia is prone to occur, which in turn causes various serious complications. Mask ventilation may occur mask ventilation difficulties and flatulence ; since the introduction of nasal high-flow oxygen therapy ( HFNC ) into the operating room in 2015, its oxygenation method has been shown to be able to significantly improve blood oxygen when used alone in pre-oxygenation. When tracheal intubation is performed, HFNC can still maintain ventilation in the patient 's nose, so HFNC can combine the advantages of both masks to perform pre-oxygenation. There are few studies on the effect of HFNC on apnea oxygenation in children in the operating room.
The present invention discloses a medicine composition for curing functional dyspepsia, which comprises the following raw materials (wt%) of medicine: 11.65 wt. % of combined spicebush root, 11.65 wt. % of areca seed, 9.30 wt. % of finger citron, 9.30 wt. % of curcuma root, 2.34 wt. % of agilawood, 23.23 wt. % of dandelion, 23.23 wt. % of calcined concha arcae and 9.30 wt. % of codonopsis pilosula. The present invention can be prepared into a conventional dosage form such as oral medicinal liquid, tablets, capsules, granules, injections, etc. The present invention also provides an improved preparation method for a medicine composition. The medicine composition can cure functional dyspepsia and can be mainly used for symptoms of stomach distention or stomachache, eructation, acid regurgitation, nausea, loss of appetite, dry mouth, bitter taste, dyschezia or colonic stasis, etc. caused by qi stagnation in the spleen and the stomach and internal heat.
The invention relates to a process for preparation of dispensing granules of scutellaria root, belonging to the technical field of preparation of traditional Chinese medicine dispensing granules. The process for preparation comprises the following procedures: for the first decoction, 8-12 times of decoction pieces of scutellaria root water and 1-2.5% of quality of decoction pieces of scutellaria CaO are charged, stirred evenly and heated to boiling state and then decocting pieces of scutellaria root is charged and decocted for 1-3 hours. For the second decoction, 6-10 times of decoction pieces of scutellaria root water is charged and decocted 0.5-2.5 hours. The decocting liquid of two decoctions is mixed and filtered, and the filtered liquid is depressed and concentrated into clear paste with 1.08-1.14 relative density under evacuation of 0.06-0.09 MPa and temperature of 50-60 DEG C. The clear paste is spray-dried and prepared into dry extract. Auxiliary material is charged according to mass ratio of decoction pieces of scutellaria root and dextrin or lactose or maltodextrin 100:1.2-3.8 and magnesium stearic acid is charged according to mass ratio of decoction pieces of scutellaria root and magnesium stearic acid 100:0.05-0.15 and mixed evenly. Granules with 18-40 mesh sieves are prepared by dry granulating method and integrated, and then disppensing granules of scutellaria root are obtained. The process for preparation has simple procedures and reasonable process and the medical effective components can not be damaged, thereby the content of baicalin in the obtained dispensing granules scutellaria root is no less than 150mg/g.
PROBLEM TO BE SOLVED: To obtain the subject material useful as a prophylactic and/or treating agent for a disease associated with apoptosis, e.g. an infectious disease, hypofunction or hyperfunction of immunity or cerebral function, or tumor. SOLUTION: This apoptosis suppressing material has the following characteristics. (1) Existing in a culture supernatant of RPMI8866 cell or that of ATL-2 cell. (2) Having a molecular weight of 100-600. (3) Having a suppressing activity against apoptosis of B104 cell, CTLL-2 cell and Jurkat cell. (4) Free from the loss of the apoptosis suppressing activity by a heat treatment.
This is a 5-year multi-center observational prospective longitudinal cohort study to to establish the large COPD cohort and biological database in China, including COPD subjects( n= 3000) and GOLD 0 subjects (n= 800).Sites Investigators will be respiratory physicians working in the respiratory department of our sites, which must be tier 2 or tier 3 hospitals in China, with the equipment and ability to conduct pulmonary function test, HRCT.Patients must meet all the inclusion criteria and none of the exclusion criteria.No additional investigational drugs will be applied to the patients. Full analysis set will be used for all analyses. Missing data will be analysed as it is. Statistical analysis will be conducted by epidemiology \& statistics work group from Chinese Academy of Sciences, using SAS and SUDAAN software. An electronic data capture system will be used in this study. Paper-based questionnaire administration will also be used.Questionnaire variables will be checked before data entry.During the study, PI will be in charge of the monitoring of the whole procedure. Two working group will do the data cleaning and data analysing.
To investigate the clinical characteristics of Eagle syndrome (ES) and evaluate psychological distress of the patients. Ten cases of ES were enrolled, clinical characteristics and management were analyzed. Psychological disorders of the patients were assessed by the test of self-rating anxiety scale (SAS) and self-rating depression scale (SDS). There were 8 females and 2 males varying from 34 to 56 years with a mean age of 44.86 ± 8.38 years. The main complaints included foreign body sensation of pharynx, odynophagia, vertigo with turning of the head-neck, pain of anterolateral neck, and toothache. Three cases were right-side affected, 6 cases were left-sided and 1 case was bilateral. Radiographic examination showed the elongated styloid process of bilateral in all cases, however, hypertrophy, improper inclination, abnormal angulation of styloid process and more complete calcification of stylohoid ligament of the complained side were observed compared to the opposite side. Eight cases suffered from anxiety and/or depression. A surgical intervention was carried out on 6 patients to resect the elongated styloid process, the symptoms and mental distress disappeared after the operation and no recurrence was found in their follow-ups. Meticulous interrogation of illness history, proper examination, and radiological studies may be valuable in diagnostic confirmation of ES. It is the hyperostosis, abnormal angulation of the styloid process rather than the simple elongation which is more likely to be attributed to the development of ES. Psychological disorders in ES patients were observed in our study and should be paid more attention in the future research.
Thermoregulation is a fundamental homeostatic function in mammals mediated by the central nervous system. The framework of the central circuitry for thermoregulation lies in the hypothalamus and brainstem. The preoptic area (POA) of the hypothalamus integrates cutaneous and central thermosensory information into efferent control signals that regulate excitatory descending pathways through the dorsomedial hypothalamus (DMH) and rostral medullary raphe region (rMR). The cutaneous thermosensory feedforward signals are delivered to the POA by afferent pathways through the lateral parabrachial nucleus, while the central monitoring of body core temperature is primarily mediated by warm-sensitive neurons in the POA for negative feedback regulation. Prostaglandin E2, a pyrogenic mediator produced in response to infection, acts on the POA to trigger fever. Recent studies have revealed that this circuitry also functions for physiological responses to psychological stress and starvation. Master psychological stress signaling from the medial prefrontal cortex to the DMH has been discovered to drive a variety of physiological responses for stress coping, including hyperthermia. During starvation, hunger signaling from the hypothalamus was found to activate medullary reticular neurons, which then suppress thermogenic sympathetic outflows from the rMR for energy saving. This thermoregulatory circuit represents a fundamental mechanism of the central regulation for homeostasis.
PURPOSE:A cosmetic that is prepared by adding vitamin B6 hydrochloride and/ or L-ascorbic acid to an extract from ODORIKOSO (Lamiumalbum L. var. barbatum Franch. et Savat), thus showing safety to skins and high effect on skins as an astringent agent, without deterioration even when stored for a long time. CONSTITUTION:Stems, leaves, flowers of ODORIKOSO are crushed in a mixed solvent consisting of water and a polar solvent such as 1,3-butylene glycol or ethanol to effect extraction. Then, the extract is concentrated to give an ODORIKOSO extract. The resultant extract is added to a cosmetic by 0.01- 10wt% based on the cosmetic, then 0.001-1, preferably 0.01-0.2wt% of vitamin B6 hydrochloride and 0.001-1, preferably 0.05-0.2wt% of L-ascorbic acid are added to the cosmetic to give a cosmetic with skin astringency. EFFECT:Its astringent effect is increased to prevent make-up from stripping by sweat or so and breeding from fine cuts after shaving.
Methods, apparatuses, and systems are disclosed for analyzing quality control (QC) strategies that are applied to testing processes an analyte in order to meet an acceptable level of probability of patient harm that could result from incorrect test results. The measure of patient harm takes into account severity of patient harm, as well as its occurrence. Methods include calculating, based on the parameters of the QC strategies and the test apparatus, an expected number of incorrect final results E(Nuf ) due to a test system failure. The value of E(Nuf) can be used as part of a calculation of a predicted level of probability patient harm. The ratio of the acceptable level of probability of patient harm to the predicted level of probability patient harm can determine the adequacy of the QC strategies. 68422694V.1 7676912 1 (GHMatters) P102980.AU Obtain non-failure probability of error and average number of reported 910 results between failures Obtain Quality Control strategy 920 information Calculate expected number of 930 unreliable final results due to test system failure Obtain a probability that an unreliable 940 final result leads to patient harm Calculate a predicted probability of 950 patient harm Provide assessment of Quality 960 Control strategy using predicted probability of patient harm and allowable probability of patient harm
PURPOSE: A water-in-oil lip makeup composition containing natural pigment is provided to freshly use with excellent color expression, moisturization, and freshness. CONSTITUTION: A water-in-oil lip makeup composition contains natural pigment, polyol, metal ion sequestering agent, acidity adjusting agent, purified water, and surfactant. The natural pigment is sweet potato, hisandra chinensis Baillon, Curcuma longa Linne, beet, paprika or red radish pigment. The polyol is glycerin, buryleneglycol, or propylene glycol. The metal ion sequestering agent is disodium EDTA, hydroxyethylidenediphosphoate, or trisodium phosphate. The acidity adjusting agent is citric acid/sodium citrate or salicylic acid/sodium salicylate. The surfactant is ester-based surfactant or silicon-based surfactant.
Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
In this double-blind randomized clinical trial, 60 patients aged 18-60y referred to Baharlou hospital with a history of mild to moderate depression diagnosed by a psychiatrist will be presented to the researcher. After receipt of a signed informed consent form, eligible patients will participate. A general demographic questionnaire will be completed by an interviewer. Individuals are randomly divided into intervention and control groups. A 10-ml venous blood sample will be collected from each participant. The intervention group receives 50000 IU of vitamin D every 2 weeks as vitamin D supplements for 8 weeks, provided monthly. The control group receives placebo. The drug schedule of both groups (if any) will be unchanged according to the prescribing physician. After 8 weeks, blood sample will be collected from each participant. The studied indices (inflammatory (IL-1β, IL-6, hs-CRP), PTH, platelet serotonin, serum oxytocin, serum 25(OH) D, depression status, anthropometry indices) will be evaluated at beginning and end of interventional period. Data will be analyzed by statistical tests.
BACKGROUND: Parkinson's disease (PD) is a common central nervous system neurodegenerative disease. Neuroinflammation is one of the significant neuropathological hallmarks. As a traditional Chinese medicine, Safranal exerts anti-inflammatory effects in various diseases, however, whether it plays a similar effect on PD is still unclear. The study was to investigate the effects and mechanism of Safranal on PD.
METHODS: The PD mouse model was established by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine MPTP firstly. Next, the degree of muscle stiffness, neuromuscular function, motor retardation and motor coordination ability were examined by observing and testing mouse movement behavior. Immunofluorescence staining was used to observe the expression of tyrosine hydroxylase (TH). The dopamine (DA) content of the striatum was detected by High-performance liquid chromatography (HPLC). The expression of TH and NLRP3 inflammasome-related markers NLRP3, IL-1β, and Capase-1 were detected by Real-time Polymerase Chain Reaction (qRT-PCR) and western blotting (WB) respectively.
RESULTS: Through behavioral testing, Parkinson's mouse showed a higher muscle stiffness and neuromuscular tension, a more motor retardation and activity disorders, together with a worse motor coordination compared with sham group. Simultaneously, DA content and TH expression in the striatum were decreased. However, after using Safranal treatment, the above pathological symptoms of Parkinson's mouse all improved compared with Safranal untreated group, the DA content and TH expression were also increased to varying degrees. Surprisingly, it observed a suppression of NLRP3 inflammation in the striatum of Parkinson's mouse.
CONCLUSIONS: Safranal played a neuroprotective effect on the Parkinson's disease and its mechanism was related to the inhibition of NLRP3 inflammasome activation.
Ribosome inactivator proteins known as nigrin I1 and nigrin I2 from the plant Sambucus nigra L., process for obtaining them and preparation Type 2 nigrin I1 and nigrin I2 (comprising two polypeptide chains) have relative molecular masses of 59,500 daltons in the absence of a reducing agent. They have two B chains and one A chain joined by disulphide bridges which in the presence of a reducing agent have an Mr of 33,500 and 34,000 daltons for the B chains and 26,000 for the A chain. They have the following amino acid sequences at their amine terminal ends: Nigrin I1: Chain A: Ile-Asp-Tyr-Pro-Ser-Val-Ser-Phe-Asn-Leu-Asp-Gly- Ala-Lys-Ser-Ala-Thr-Tyr-Arg-Asp. Chain B: Asp-Gly-Glu-Thr-Xaa-Thr-Leu-Arg-Thr-Ser-Phe-Thr- Arg-Asn-Ile-Val-Gly-Xaa-Asp-Gly. Nigrin I2: Chain A: Ile-Asp-Tyr-Pro-Ser-Val-Ser-Phe-Asn-Leu-Asp-Gly- Ala-Lys-Ser-Ala-Thr-Tyr-Arg-Asp-Phe-Leu-Ser-Asn. Chain B: Asp-Gly-Glu-Thr-Xaa-Thr-Leu-Arg-Thr-Ser-Phe-Thr- Arg-Asn-Ile-Val-Gly-Xaa-Asp-Gly. The general process for obtaining RIPs from Sambucus nigra L. according to this invention comprises isolating them from broths of Sambucus nigra L., including a first extraction operation including an aqueous solution based on sodium chloride and monosodium phosphate to obtain an extract which is capable of inhibiting protein synthesis, followed by the purification of this using affinity, molecular exclusion and ion exchange chromatography techniques. Nigrin I1 and nigrin I2 are used as ribonucleic acid inactivators and inhibitors of protein biosynthesis.
Arrhythmogenic cardiomyopathy (ACM) is a familial heart disease characterized by cardiac dysfunction, arrhythmias, and myocardial inflammation. Exercise and stress can influence the disease's progression. Thus, an investigation of whether a high-fat diet (HFD) contributes to ACM pathogenesis is warranted. In a robust ACM mouse model, 8-week-old Desmoglein-2 mutant (Dsg2mut/mut) mice were fed either an HFD or rodent chow for 8 weeks. Chow-fed wildtype (WT) mice served as controls. Echo- and electrocardiography images pre- and post-dietary intervention were obtained, and the lipid burden, inflammatory markers, and myocardial fibrosis were assessed at the study endpoint. HFD-fed Dsg2mut/mut mice showed numerous P-wave perturbations, reduced R-amplitude, left ventricle (LV) remodeling, and reduced ejection fraction (%LVEF). Notable elevations in plasma high-density lipoprotein (HDL) were observed, which correlated with the %LVEF. The myocardial inflammatory adipokines, adiponectin (AdipoQ) and fibroblast growth factor-1, were substantially elevated in HFD-fed Dsg2mut/mut mice, albeit no compounding effect was observed in cardiac fibrosis. The HFD not only potentiated cardiac dysfunction but additionally promoted adverse cardiac remodeling. Further investigation is warranted, particularly given elevated AdipoQ levels and the positive correlation of HDL with the %LVEF, which may suggest a protective effect. Altogether, the HFD worsened some, but not all, disease phenotypes in Dsg2mut/mut mice. Notwithstanding, diet may be a modifiable environmental factor in ACM disease progression.
Perifosine 208: A Phase II Trial of Two Schedules of Perifosine in Combination with Endocrine Therapy (Tamoxifen) for Patients with Estrogen Receptor or Progesterone Receptor Positive Metastatic Breast Cancer Dosage: Arm A: 50 mg Perifosine /day p.o. .Endocrine therapy continued at same dose and schedule. Arm B: 900 Perifosine weekly. Endocrine therapy continued at same dose and schedule.
Polysaccharides are one of the most important and widely used bioactive components of natural products, which can be used to treat metabolic diseases. Natural polysaccharides (NPs) have been the subject of much study and research in the field of treating obesity in recent years. Studies in the past have demonstrated that mitochondria are important for the initiation, progression, and management of obesity. Additionally, NPs have the ability to improve mitochondrial dysfunction via a variety of mechanisms. This review summarized the relationship between the structure of NPs and their anti-obesity activity, focusing on the anti-obesity effects of these compounds at the mitochondrial level. We discussed the association between the structure and anti-obesity action of NPs, including molecular weight, monosaccharide composition, glycosidic linkage, conformation and extraction methods. Furthermore, NPs can demonstrate a range of functions in adipose tissue, including but not limited to improving the mitochondrial oxidative respiratory chain, inhibiting oxidative stress, and maintaining mitochondrial mass homeostasis. The purpose of this work is to acquire a thorough understanding of the function that mitochondria play in the anti-obesity effects of NPs and to offer fresh insights for the investigation of how NPs prevent obesity and the creation of natural anti-obesity medications.
Prepn. of liq. pharmaceutical compsns. contg. N-dimethyl laminoisopropyl-thiophenylpyridylamine (I) in the form of a homogeneous soln. administrable as an aerosol comprises dissolving (I) in a mixt. of at least one pharmacologically acceptable solvents and at least one fluorochlorocarbon propellant in the presence of a solubilising agent comprising benzenesulphonic acid, toluenesulphonic acid camphor-sulphonic acid and/or N-cyclohexylsulphamic acid. The solubilising agents prevent (I) from precipitating in the presence of the propellant; this ensures a uniform distribution of (I) and prevents blockage of the aerosol nozzle.
Conjugates of synthetic nanocarriers, complexed with syngeneic (self) proteins adducted with haptens or other poorly immunogenic antigens (antigens of low immunogenicity), elicit selective humoral responses or antibodies against the hapten or antigen and not to self-protein. Compositions include these conjugates, which can be used as vaccines. Methods of making and using them are described herein. In a typical embodiment, a conjugate including a hapten or antigen of low immunogenicity associated with a particular disease (e.g., infection, cancer) can be used as a vaccine by eliciting antibodies that specifically neutralize the hapten or antigen. These hapten (and other poorly immunogenic antigen)-carrying nanocarriers selectively target antigen presenting cells resulting in a strong anti-hapten humoral response, and thus find use in vaccines for cancer (e.g., cancers of lung, cervix, breast, brain, liver pancreas, ovaries, skin, etc.), infectious diseases and inflammatory-mediated diseases, as well as for autoimmune disorders.
A min. of 800 patients referred to colonoscopy at Aalborg University Hospital. The 800 patients are from the out patient clinic. A mix of screening and non-screening patients.